Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers
- PMID: 23945504
- PMCID: PMC4046103
- DOI: 10.1097/QAD.0b013e32835f6b0c
Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers
Abstract
Objective: To investigate the relationship between inflammatory [interleukin-6 (IL-6) and C-reactive protein (CRP)] and coagulation (D-dimer) biomarkers and cancer risk during HIV infection.
Design: A prospective cohort.
Methods: HIV-infected patients on continuous antiretroviral therapy (ART) in the control arms of three randomized trials (N=5023) were included in an analysis of predictors of cancer (any type, infection-related or infection-unrelated). Hazard ratios for IL-6, CRP and D-dimer levels (log2-transformed) were calculated using Cox models stratified by trial and adjusted for demographics and CD4+ cell counts and adjusted also for all biomarkers simultaneously. To assess the possibility that biomarker levels were elevated at entry due to undiagnosed cancer, analyses were repeated excluding early cancer events (i.e. diagnosed during first 2 years of follow-up).
Results: During approximately 24,000 person-years of follow-up (PYFU), 172 patients developed cancer (70 infection-related; 102 infection-unrelated). The risk of developing cancer was associated with higher levels (per doubling) of IL-6 (hazard ratio 1.38, P<0.001), CRP (hazard ratio 1.16, P=0.001) and D-dimer (hazard ratio 1.17, P=0.03). However, only IL-6 (hazard ratio 1.29, P=0.003) remained associated with cancer risk when all biomarkers were considered simultaneously. Results for infection-related and infection-unrelated cancers were similar to results for any cancer. Hazard ratios excluding 69 early cancer events were 1.31 (P=0.007), 1.14 (P=0.02) and 1.07 (P=0.49) for IL-6, CRP and D-dimer, respectively.
Conclusion: Activated inflammation and coagulation pathways are associated with increased cancer risk during HIV infection. This association was stronger for IL-6 and persisted after excluding early cancer. Trials of interventions may be warranted to assess whether cancer risk can be reduced by lowering IL-6 levels in HIV-positive individuals.
Conflict of interest statement
Similar articles
-
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.PLoS One. 2016 May 12;11(5):e0155100. doi: 10.1371/journal.pone.0155100. eCollection 2016. PLoS One. 2016. PMID: 27171281 Free PMC article.
-
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.J Infect Dis. 2011 Jun 1;203(11):1637-46. doi: 10.1093/infdis/jir134. J Infect Dis. 2011. PMID: 21592994 Free PMC article. Clinical Trial.
-
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.PLoS Med. 2008 Oct 21;5(10):e203. doi: 10.1371/journal.pmed.0050203. PLoS Med. 2008. PMID: 18942885 Free PMC article.
-
The Effect of Rosuvastatin on Plasma/Serum Levels of High-Sensitivity C-Reactive Protein, Interleukin-6, and D-Dimer in People Living with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis.AIDS Res Hum Retroviruses. 2021 Nov;37(11):821-833. doi: 10.1089/AID.2020.0273. Epub 2021 Jun 14. AIDS Res Hum Retroviruses. 2021. PMID: 33913752
-
Biomarkers of immune dysfunction in HIV.Curr Opin HIV AIDS. 2010 Nov;5(6):498-503. doi: 10.1097/COH.0b013e32833ed6f4. Curr Opin HIV AIDS. 2010. PMID: 20978393 Free PMC article. Review.
Cited by
-
Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV.Cancers (Basel). 2023 Jul 15;15(14):3640. doi: 10.3390/cancers15143640. Cancers (Basel). 2023. PMID: 37509301 Free PMC article.
-
The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.Viral Immunol. 2014 Jun;27(5):186-99. doi: 10.1089/vim.2013.0130. Epub 2014 May 5. Viral Immunol. 2014. PMID: 24797368 Free PMC article. Review.
-
Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns.BMC Infect Dis. 2017 Aug 22;17(1):581. doi: 10.1186/s12879-017-2676-2. BMC Infect Dis. 2017. PMID: 28830393 Free PMC article.
-
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.PLoS One. 2016 May 12;11(5):e0155100. doi: 10.1371/journal.pone.0155100. eCollection 2016. PLoS One. 2016. PMID: 27171281 Free PMC article.
-
Incidence and risk of lung cancer in HIV-infected patients.J Cancer Res Clin Oncol. 2013 Nov;139(11):1781-94. doi: 10.1007/s00432-013-1477-2. Epub 2013 Jul 28. J Cancer Res Clin Oncol. 2013. PMID: 23892408 Free PMC article. Review.
References
-
- Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1–19. - PubMed
-
- Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67. - PubMed
-
- Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–736. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous